4d
New Scientist on MSNCAR T-cells enable record-breaking 18-year nerve cancer remissionA person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...
CAR-T-cell therapy treated a girl with a rare childhood cancer, raising hopes for future recipients of the approach.
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...
Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...
Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results